Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine With subacute ischemic cardiomyopathy

Journal of the American Heart Association

Volumn 4, Issue 4, 2015, Pages

  Bagno, Luiza L ^a   Kanashiro Takeuchi, Rosemeire M ^a   Suncion, Viky Y ^a   Golpanian, Samuel ^a   Karantalis, Vasileios ^a   Wolf, Ariel ^a   Wang, Bo ^a   Premer, Courtney ^a   Balkan, Wayne ^a   Rodriguez, Jose ^a   Valdes, David ^a   Rosado, Marcos ^a   Block, Norman L ^a,b   Goldstein, Peter ^a,c   Morales, Azorides ^a   Cai, Ren Zhi ^a,b   Sha, Wei ^a,b   Schally, Andrew V ^a,b   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GRECC Miami Veterans Affairs Healthcare System   (United States)

^c Biscayne Pharmaceuticals   (United States)

Author keywords

Diastolic function; Growth hormone releasing hormone; Heart failure; Myocardial infarction; Remodeling

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; MR 409; PLACEBO; UNCLASSIFIED DRUG; CREATINE KINASE MB; CREATINE KINASE MM; GHRH(1-29)N-CH3, N-ME-TYR(1)-ALA(2)-ORN(12)-ABU(15)-ORN(21)-NLE(27)-ASP(28)-; SERMORELIN; TROPONIN I;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CELL PROLIFERATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; YORKSHIRE PIG; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CARDIAC MUSCLE; CICATRIX; COMPLICATION; DRUG EFFECTS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PIG;

ANIMALS; CICATRIX; CREATINE KINASE, MB FORM; CREATINE KINASE, MM FORM; FEMALE; GROWTH HORMONE-RELEASING HORMONE; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; SERMORELIN; SWINE; TROPONIN I; VENTRICULAR REMODELING;

EID: 84990876778     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001464     Document Type: Article

References (42)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres J, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Twofighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129: e28-e292.
2. Joffe SW, Webster K, McManus DD, Kiernan MS, Lessard D, Yarzebski J, Darling C, Gore JM, Goldberg RJ. Improved survival after heart failure: a community-based perspective. J Am Heart Assoc. 2013;2:e000053 doi: 10. 1161/JAHA.113.000053.
3. Sacca L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail. 2009;2:151-156.
4. Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, Nelson KH, Gerstenblith G, Difede Velazquez DL, Breton E, Sitammagari K, Schulman IH, Taldone SN, Williams AR, Sanina C, Johnston PV, Brinker J, Altman P, Mushtaq M, Trachtenberg B, Mendizabal AM, Tracy M, Da Silva J, McNiece IK, Lardo AC, George RT, Hare JM, Heldman AW. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res. 2014;114:1292-1301.
5. Karantalis V, DiFede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, Fishman J, Pattany P, McNiece I, Conte J, Schulman S, Wu K, Shah A, Breton E, Davis-Sproul J, Schwarz R, Feigenbaum G, Mushtaq M, Suncion VY, Lardo AC, Borrello I, Mendizabal A, Karas TZ, Byrnes J, Lowery M, Heldman AW, Hare JM. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: the prospective randomized study of mesenchymal stem cell therapy in patients undergoing cardiac surgery (PROMETHEUS) trial. Circ Res. 2014;114:1302-1310.
6. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311:62-73.
7. Kanashiro-Takeuchi RM, Schulman IH, Hare JM. Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol. 2011;51:619-625.
8. Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, Treuer AV, Lamirault G, Dulce R, Hurtado M, Song Y, Block NL, Rick F, Klukovits A, Hu Q, Varga JL, Schally AV, Hare JM. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA. 2010;107:2604-2609.
9. Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG, Dulce R, Treuer AV, Florea V, Rodrigues CO, Paulino EC, Hatzistergos KE, Selem SM, Gonzalez DR, Block NL, Schally AV, Hare JM. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA. 2012;109:559-563.
10. Cittadini A, Marra AM, Arcopinto M, Bobbio E, Salzano A, Sirico D, Napoli R, Colao A, Longobardi S, Baliga RR, Bossone E, Sacca L. Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled singleblind study. JACC Heart Fail. 2013;1:325-330.
11. Granata R, Trovato L, Gallo MP, Destefanis S, Settanni F, Scarlatti F, Brero A, Ramella R, Volante M, Isgaard J, Levi R, Papotti M, Alloatti G, Ghigo E. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res. 2009;83:303-312.
12. Florea V, Majid SS, Kanashiro-Takeuchi RM, Cai RZ, Block NL, Schally AV, Hare JM, Rodrigues CO. Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proc Natl Acad Sci USA. 2014;111:17260-17265.
13. Aimaretti G, Baldelli R, Corneli G, Bellone S, Rovere S, Croce C, Ragazzoni F, Giordano R, Arvat E, Bona G, Ghigo E. GHRH and GH secretagogues: clinical perspectives and safety. Pediatr Endocrinol Rev. 2004;2(Suppl 1):86-92.
14. Kiaris H, Schally AV, Kalofoutis A. Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm. 2005;70:1-24.
15. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809-814.
16. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R. Randomised, double-blind, placebocontrolled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-1237.
17. Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1995;92:4872-4876.
18. Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, Kovacs M, Jaszberenyi M, He J, Rick FG, Popovics P, Kanashiro-Takeuchi R, Hare JM, Block NL, Zarandi M. Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides. 2014;52:104-112.
19. McCall FC, Telukuntla KS, Karantalis V, Suncion VY, Heldman AW, Mushtaq M, Williams AR, Hare JM. Myocardial infarction and intramyocardial injection models in swine. Nat Protoc. 2012;7:1479-1496.
20. Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Feigenbaum GS, Margitich IS, Mazhari R, Boyle AJ, Zambrano JP, Rodriguez JE, Dulce R, Pattany PM, Valdes D, Revilla C, Heldman AW, McNiece I, Hare JM. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107:913-922.
21. Dash R, Chung J, Ikeno F, Hahn-Windgassen A, Matsuura Y, Bennett MV, Lyons JK, Teramoto T, Robbins RC, McConnell MV, Yeung AC, Brinton TJ, Harnish PP, Yang PC. Dual manganese-enhanced and delayed gadolinium-enhanced MRI detects myocardial border zone injury in a pig ischemia-reperfusion model. Circ Cardiovasc Imaging. 2011;4:574-582.
22. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial GD-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318-3326.
23. Mill JG, Zornoff LA, Okoshi MP, Okoshi K, Padovani CR, Sugisaki M, Leite CM, Cicogna AC. The early administration of growth hormone results in deleterious effects on ventricular remodeling after acute myocardial infarction. Arq Bras Cardiol. 2005;84:115-121.
24. Laguens RP, Castagnino HE, Jorg ME, Hamamura S. Reduced injury and scar in acute myocardial infarctions treated with human growth hormone. Jpn Heart J. 1998;39:809-817.
25. Jin H, Yang R, Lu H, Ogasawara AK, Li W, Ryan A, Peale F, Paoni NF. Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res. 2002;12:208-215.
26. Hatzistergos KE, Mitsi AC, Zachariou C, Skyrlas A, Kapatou E, Agelaki MG, Fotopoulos A, Kolettis TM, Malamou-Mitsi V. Randomised comparison of growth hormone versus IGF-1 on early post-myocardial infarction ventricular remodelling in rats. Growth Horm IGF Res. 2008;18:157-165.
27. MacAndrew JT, Ellery SS, Parry MA, Pan LC, Black SC. Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury. Eur J Pharmacol. 2001;432:195-202.
28. Dubreuil P, Brazeau P, Moreau S, Farmer C, Coy D, Abribat T. The use of pigs as an animal model to evaluate the efficacy, potency and specificity of two growth hormone releasing factor analogues. Growth Horm IGF Res. 2001;11:173-186.
29. Mewton N, Elbaz M, Piot C, Ovize M. Infarct size reduction in patients with STEMI: why we can do it!. J Cardiovasc Pharmacol Ther. 2011;16:298-303.
30. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.
31. Kanashiro-Takeuchi R, Szalontay L, Schally A, Takeuchi L, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai R, Block N, Hare J, Rick F. (2015). New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget, 5. Retrieved from http://www.impactjournals.com/oncotarget/index.php?journal= oncotarget&page=article&op=view&path%5B%5D=3303.
32. Larose E, Rodes-Cabau J, Pibarot P, Rinfret S, Proulx G, Nguyen CM, Dery JP, Gleeton O, Roy L, Noel B, Barbeau G, Rouleau J, Boudreault JR, Amyot M, De Larochelliere R, Bertrand OF. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol. 2010;55:2459-2469.
33. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Stiermaier T, Blazek S, Schuler G, Thiele H. Prognosis after ST-elevation myocardial infarction: a study on cardiac magnetic resonance imaging versus clinical routine. Trials. 2014;15:249.
34. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous NPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031-2037.
35. Watanabe E, Abbasi SA, Heydari B, Coelho-Filho OR, Shah R, Neilan TG, Murthy VL, Mongeon FP, Barbhaiya C, Jerosch-Herold M, Blankstein R, Hatabu H, van der Geest RJ, Stevenson WG, Kwong RY. Infarct tissue heterogeneity by contrast-enhanced magnetic resonance imaging is a novel predictor of mortality in patients with chronic coronary artery disease and left ventricular dysfunction. Circ Cardiovasc Imaging. 2014;7:887-894.
36. Bello D, Einhorn A, Kaushal R, Kenchaiah S, Raney A, Fieno D, Narula J, Goldberger J, Shivkumar K, Subacius H, Kadish A. Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease. Magn Reson Imaging. 2011;29:50-56.
37. Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation. 1995;92:334-341.
38. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, Di Carli MF, Reynolds HG, Stevenson WG, Kwong RY. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32-39.
39. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, Carr JC, Holly TA, Lloyd-Jones D, Klocke FJ, Bonow RO. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94:730-736.
40. Geltman EM. Infarct size as a determinant of acute and long-term prognosis. Cardiol Clin. 1984;2:95-103.
41. Azevedo CF, Amado LC, Kraitchman DL, Gerber BL, Osman NF, Rochitte CE, Edvardsen T, Lima JA. Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging. Eur Heart J. 2004;25:1419-1427.
42. Penna C, Settanni F, Tullio F, Trovato L, Pagliaro P, Alloatti G, Ghigo E, Granata R. GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of risk and safe pathways. Endocrinology. 2013; 154:1624-1635.